Callahan Advisors LLC Raises Stake in STERIS plc (NYSE:STE)

Callahan Advisors LLC raised its stake in STERIS plc (NYSE:STE - Free Report) by 9.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,569 shares of the medical equipment provider's stock after acquiring an additional 3,286 shares during the period. Callahan Advisors LLC's holdings in STERIS were worth $7,928,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Magnolia Capital Advisors LLC boosted its position in STERIS by 1.9% in the 4th quarter. Magnolia Capital Advisors LLC now owns 2,534 shares of the medical equipment provider's stock valued at $521,000 after buying an additional 48 shares during the last quarter. SkyView Investment Advisors LLC raised its stake in STERIS by 1.6% during the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider's stock worth $765,000 after acquiring an additional 51 shares during the period. Park Edge Advisors LLC raised its stake in STERIS by 1.1% during the fourth quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider's stock worth $958,000 after acquiring an additional 51 shares during the period. Opal Wealth Advisors LLC raised its stake in STERIS by 5.7% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,118 shares of the medical equipment provider's stock worth $230,000 after acquiring an additional 60 shares during the period. Finally, Sage Private Wealth Group LLC raised its stake in STERIS by 4.1% during the fourth quarter. Sage Private Wealth Group LLC now owns 1,537 shares of the medical equipment provider's stock worth $316,000 after acquiring an additional 61 shares during the period. Institutional investors and hedge funds own 94.69% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on STE. Stephens restated an "overweight" rating and issued a $240.00 price target on shares of STERIS in a research note on Thursday, February 6th. Piper Sandler raised their target price on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. StockNews.com cut shares of STERIS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, October 29th. JMP Securities restated a "market outperform" rating and issued a $265.00 price target on shares of STERIS in a research report on Thursday, February 6th. Finally, Needham & Company LLC restated a "hold" rating on shares of STERIS in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $258.75.

Insider Activity

In other news, SVP Cary L. Majors sold 1,682 shares of the business's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the sale, the senior vice president now owns 11,372 shares of the company's stock, valued at $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.14% of the company's stock.

STERIS Price Performance

STE stock traded down $0.36 during trading on Friday, hitting $220.43. 412,247 shares of the stock traded hands, compared to its average volume of 474,275. STERIS plc has a one year low of $197.82 and a one year high of $248.24. The stock has a market cap of $21.66 billion, a price-to-earnings ratio of 46.80 and a beta of 0.84. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. The company has a 50 day simple moving average of $213.47 and a 200 day simple moving average of $223.64.

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Equities analysts expect that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be issued a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 1.03%. The ex-dividend date is Thursday, February 20th. STERIS's dividend payout ratio (DPR) is presently 48.41%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.